LATEST PRESS RELEASES

article placeholder
Featured245 views7 min read

Sweetwater Brewing Unveils Modern Rebrand

Tilray Brands
ATLANTA, April 25, 2024 -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast and a subsidiary of Tilray Brands, Inc., (NASDAQ: TLRY and TSX: TLRY), today announced a design refresh to make the Sweetwater brand more impactful, cohesive, and memorable to consumers. SweetWater’s upda... Read More...
341 views4 min read

Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence

Optimi Health
VANCOUVER, British Columbia, Jan. 19, 2024 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, is pleased to announce it has been granted an amendment to its H... Read More...
2903 views8 min read

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

Psyence Group
Psyence Group Inc.TORONTO, Jan. 16, 2024 -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that its subsidiary, Psyence Biomedical Ltd ("Pubco"), has entered into a definitive securities purc... Read More...
109 views4 min read

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

Revive Therapeutics
Revive Therapeutics Ltd.TORONTO, Jan. 10, 2024 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation devel... Read More...
709 views4 min read

Lobe Sciences Provides Company Review of 2023

Lobe Sciences
12-month data confirming that L-130 is the first reported stable oral psilocinFirst-in-Man clinical data demonstrates the superior PK profile of L-1302023 sales of $1.1M (CAD) for Altemia®VANCOUVER, British Columbia, January 08, 2024--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focu... Read More...
1186 views9 min read

Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin
- Intravenous ("IV") CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment -- Intramuscular ("IM") dosing of SPL028 produced robust, short-duration psychedelic effects in the majority of participants -- Both IV and IM routes were saf... Read More...
1184 views3 min read

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Silo Pharma
Silo Pharma, Inc.Final validation report expected in first quarter 2024ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announce... Read More...
984 views10 min read

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs

Cybin
- Recently announced positive Phase 2 topline data in Major Depressive Disorder ("MDD") with 79% of patients in remission from depression after two doses of CYB003 (12mg) -- Programs supported by robust intellectual property portfolio with 40 granted patents and over 170 pending applications -- Multinational operations support scaling to ... Read More...
473 views5 min read

Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats

Optimi Health
Optimi Health Corp.VANCOUVER, British Columbia, Jan. 03, 2024 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA, proudly announces a significant milestone in the granting of i... Read More...
541 views2 min read

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Silo Pharma
Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced an update on its do... Read More...
865 views3 min read

Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

Revive Therapeutics
TORONTO, Dec. 20, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the results of its annual general and special meeting of shareholde... Read More...
221 views4 min read

Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine

Revive Therapeutics
Revive Therapeutics Ltd.TORONTO, Dec. 18, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a collaboration agreemen... Read More...
826 views4 min read

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

Mydecine Innovations Group
VANCOUVER, British Columbia, Dec. 18, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by... Read More...
68 views4 min read

Cedar Clinical Research selected as clinical research site for Beckley Psytech’s Phase 2b Study

Numinus Wellness
VANCOUVER, BC, Dec. 15, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is proud to announce that its research site, Cedar Clinical Research (CCR), has bee... Read More...
63 views4 min read

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

Numinus Wellness
VANCOUVER, BC, Dec. 13, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, congratulates the Multidisciplinary Association of Psychedelics Studies ("MAPS" or "MAPS PBC") for its submission of a new drug a... Read More...
M & A72 views8 min read

Red Light Holland’s GMP Manufactured Psilocybin Microdosing Capsules Aimed to Be Distributed in Emerging Markets Pass Five Month Stability Testing by CCrest Laboratories in Montreal, Canada

Red Light Holland
Red Light Holland's natural psilocybin microdosing capsules developed from psilocybin truffles grown in the company's farm in The Netherlands, have received the results of five months stability tests for the capsules, confirming stability of psilocybin.Confirmation of stability of psilocybin, at five months, follows the previously announc... Read More...
569 views4 min read

Lobe Sciences Provides Update on L-130 Clinical Program

Lobe Sciences
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybinL-130 Phase 2 Trial Planned for 2024VANCOUVER, British Columbia, December 07, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe"), a biopharmaceutical company focused on developing transformative medicines t... Read More...
162 views9 min read

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin
- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose -- Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline betwe... Read More...
404 views4 min read

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

Optimi Health
VANCOUVER, British Columbia, Nov. 28, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, streng... Read More...
25 views4 min read

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Silo Pharma
MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company ... Read More...
Calendar29 views2 min read

Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023

Cybin
- Company to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder -TORONTO, November 16, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to... Read More...
M & A25 views8 min read

Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

Psyence Group
TORONTO, Nov. 15, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration stat... Read More...
265 views4 min read

US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives

BetterLife Pharma
VANCOUVER, British Columbia, Nov. 15, 2023 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that its patent application for BETR-001 and LSD d... Read More...
26359 views7 min read

Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders

Cybin
TORONTO, November 14, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previous... Read More...
37 views4 min read

Red Light Holland Re-Engages Former Health Minister, the Honourable, Tony P. Clement, as Senior Advisor to Advisory Board

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - November 14, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreati... Read More...
M & A35 views8 min read

Red Light Holland Psilocybin Microdosing Capsules Aimed to Be Distributed in Emerging Markets Pass Four Month Stability Testing by C-CREST Laboratories in Montreal, Canada

Red Light Holland
Red Light Holland's natural psilocybin microdosing capsules developed from psilocybin truffles grown in the Company's farm in The Netherlands, have received the results of four months stability tests for the capsules, confirming stability of psilocybin.Confirmation of stability of psilocybin, at four months, follows the previously announc... Read More...
34 views8 min read

Cybin Announces up to US$64 Million Offering of Units

Cybin
TORONTO, November 10, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten ... Read More...
37 views2 min read

Optimi Health Resolves Dispute

Optimi Health
VANCOUVER, British Columbia, Nov. 10, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi") is pleased to announce the successful resolution of a dispute that arose in connection with a termination notice related to a supply agreement ("the Supply Agreement") signed with a private entity on May 4, 2023. Optimi is pl... Read More...
16 views2 min read

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Silo Pharma
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traum... Read More...
35 views7 min read

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

Revive Therapeutics
Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medi... Read More...
26 views8 min read

Red Light Holland Engages Dr. Taras Nahirny, as Medical Advisor, to Help with Distribution of Company’s Homogenized Psilocybin Microdosing Capsules and Help Advocate for Easier, but Regulated Access in Canada

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - November 2, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilo... Read More...
13 views3 min read

Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing

Optimi Health
Optimi Health Corp.VANCOUVER, British Columbia, Nov. 02, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is plea... Read More...
18 views12 min read

Breakthrough Results: Cybin’s CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose

Cybin
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) -- For reference, pooled data from 232... Read More...
26 views8 min read

Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline

Cybin
- Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET -- Complete Phase 2 topline data for CYB003 in MDD expected in Q4 2023 -TORONTO, November 01, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharma... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!